Sivik Global Healthcare LLC Sells 35,000 Shares of Smith & Nephew SNATS, Inc. $SNN

Key Points

• Sivik Global Healthcare LLC sold 35,000 shares of Smith & Nephew, trimming its stake by 21.9% to 125,000 shares valued at $4.101 million, making the stock its 21st largest position and ~1.2% of its holdings.
• Other institutions boosted positions significantly — Goldman Sachs raised its stake 49.2% to 1,771,401 shares (~$50.26M) and Bank of America increased its holding 139.9% to 987,274 shares; overall institutional ownership is 25.64%.
• Dividend announced: Smith & Nephew will pay $0.482 per share on May 27 to holders of record March 27 (article reports a 304.0% yield and an ex-dividend date of March 27).

Sivik Global Healthcare LLC cut its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 21.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,000 shares of the medical equipment provider's stock after selling 35,000 shares during the quarter. Smith & Nephew SNATS accounts for approximately 1.2% of Sivik Global Healthcare LLC's holdings, making the stock its 21st largest position. Sivik Global Healthcare LLC's holdings in Smith & Nephew SNATS were worth $4,101,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Goldman Sachs Group Inc. raised its holdings in shares of Smith & Nephew SNATS by 49.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider's stock valued at $50,255,000 after purchasing an additional 583,809 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Smith & Nephew SNATS by 139.9% during the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider's stock valued at $35,828,000 after purchasing an additional 575,666 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Smith & Nephew SNATS by 45.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 937,943 shares of the medical equipment provider's stock valued at $34,038,000 after purchasing an additional 293,418 shares during the period. Todd Asset Management LLC bought a new stake in shares of Smith & Nephew SNATS during the 3rd quarter valued at about $26,319,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Smith & Nephew SNATS by 11.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 492,025 shares of the medical equipment provider's stock valued at $17,785,000 after purchasing an additional 51,650 shares during the period. 25.64% of the stock is owned by institutional investors.

Smith & Nephew SNATS Price Performance

Shares of SNN opened at $31.72 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a 1 year low of $23.91 and a 1 year high of $38.79. The company has a 50 day simple moving average of $34.14 and a two-hundred day simple moving average of $34.12.

Smith & Nephew SNATS (NYSE:SNN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The firm had revenue of $1.60 billion for the quarter. Sell-side analysts anticipate that Smith & Nephew SNATS, Inc. will post 1.69 earnings per share for the current year.

Smith & Nephew SNATS Announces Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Friday, March 27th will be given a dividend of $0.482 per share. This represents a dividend yield of 304.0%. The ex-dividend date is Friday, March 27th.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a "hold (c+)" rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Wall Street Zen upgraded Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research report on Sunday, March 29th. Royal Bank Of Canada downgraded Smith & Nephew SNATS from an "outperform" rating to a "sector perform" rating in a research report on Monday, December 15th. Finally, Canaccord Genuity Group raised their price objective on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a "hold" rating in a research report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Smith & Nephew SNATS presently has an average rating of "Hold" and an average price target of $36.25.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.